Longaevus Technologies

Longaevus Technologies

Approaching Longevity From All Angles

Longaevus is a UK-based biotech company dedicated to advancing technologies that promote longer, healthier lives. Operating as the catalyst for innovation, we serve as the parent company, encompassing all projects in a venture creation model. This approach empowers us to accelerate the development of pioneering longevity solutions.

At Longaevus our foundational principle is full commitment to science. Our consulting team consists of world-renowned scientific experts, each at the forefront of research into the intricacies of ageing mechanisms. In just two years, Longaevus has celebrated two successful spin-off projects. Through cutting-edge biotechnology, including small molecules, gene therapy, aptamers, and more, we aim to revolutionise anti-ageing therapeutics and extend the human lifespan by two decades.

Who we are
Perspectives

Perspectives on
Ageing

The need for ageing interventions is more critical than ever. By 2050, the population over 60 years old is expected to nearly double, from 12% to 22%, leading to a 2x increase in global spending on age-related disease treatment.

Currently, there are no approved treatments for the complex process of ageing, and existing treatments merely scratch the surface by addressing symptoms . However, a healthspan revolution is underway. Thanks to advancements in OMICS approaches, AI, and cutting-edge lab techniques, we're now on the verge of uncovering the very root causes of ageing.

Unlike conventional practices, Longaevus embraces a comprehensive approach. We believe that to effectively combat ageing, we must unite various fields of science and research to address the collective root causes. It's time for a new era in human healthspan.

Longaevus approaches the problem of
ageing from 5 different directions:

Longevity Bottleneck Processes

Approach

As we age, our body experiences various detrimental processes that it cannot effectively manage. We call them «LONGEVITY BOTTLENECK» processes. These key factors, such as reactivation of retrotransposons, increased matrix stiffness, declining telomerase activity, and more, not only impose limits on human lifespan but also contribute to specific age-related conditions like cardiovascular diseases, cancer, and dementia. At Longaevus, we pinpoint diseases where these specific bottlenecks play a crucial role, addressing the underlying causes. This approach allows us to both develop best-in-class therapies and bring them to market quickly within the FDA's framework.

Approach

Our platforms

Consistently using appropriate platforms, we enhance the speed and efficacy of our target search and validation processes, followed by the development of new projects and their spin-off into independent companies.

Our platforms

To accomplish this, we have created two platforms that facilitate rapid and accurate searches for new targets: Targetome in silico platform and Excelsius ex vivo platform.

Pipeline

Integrated Venture Acceleration

Consistently using appropriate platforms, we enhance the speed and efficacy of our target search and validation processes, followed by the development of new projects and their spin-off into independent companies.

Integrated Venture Acceleration

The extracellular matrix becomes stiffer during ageing due to sugar-driven crosslinking and chronic inflammation, leading to age-related diseases. The project concentrates on developing glucosepane-breakers and protein engineering approaches to remodel the aged matrix.

To address the pressing need for new therapies related to ageing-associated diseases, we've utilised our ex vivo platform to identify 50 novel targets. These targets play a crucial role in understanding cell senescence and will aid in the development of therapies for autoimmune diseases, neurodegeneration, and various other age-related pathologies.

Elastin loss due to ageing is a key contributor to ageing-related diseases such as cardiovascular disorders (aneurysms) as well as lung and skin diseases. In this project, we showed 3 combinations of assets with a potential for a platform technology to deal with treating ageing-related elastin loss and its associated diseases.

Ageing is a multifaceted process that impacts various pathways, and we are confident that achieving success in extending lifespan requires the synergy of multiple components. The project aims to develop synergistic combinations of small molecules that can impact multiple ageing pathways and induce epigenetic reprogramming. The first combination aimed to tackle neurological ageing.

Advisory Board

Viktor Korolchuk

Viktor Korolchuk, PhD

Molecular Biologist and Member of British Society for Research on Ageing, Scientific Advisor

John Sedivy

John Sedivy, PhD

Gerontologist, Professor of Biology and a Professor of Medical Science, Scientific Advisor

Alan R. Parrish

Alan R. Parrish, PhD

Professor in Medical Pharmacology and Physiology, Scientific Advisor

Jing Yang

Jing Yang, PhD

Professor of Pharmacology, Scientific Advisor

Plamena R. Angelova

Plamena R. Angelova, PhD

Cell biophysicist, Scientific Advisor

Helen L. Birch

Helen L. Birch, PhD

Professor in Skeletal Tissue Dynamics, Scientific Advisor

Longaevus Team

Ivan Morgunov

Ivan Morgunov

Founder

Alexey Moskalev

Alexey Moskalev

Founder

Artem Avetisyan

Artem Avetisyan

Founder

Dmitry Klokov

Dmitry Klokov

Molecular Biologist, Senior Researcher

Anna Vakhrusheva

Anna Vakhrusheva

Entrepreneur in residence, CEO of Remodel

Olga Borysova

Olga Borysova

Entrepreneur in residence, CEO of Combobioscience

Faya Movchan

Faya Movchan

Computational Neuroscientist, Lab Manager

Rakhan Aimbetov

Rakhan Aimbetov

Analyst

Samira Kaziakhmedova

Samira Kaziakhmedova

Analyst

Sherif Idriss

Sherif Idriss

Entrepreneur in residence, CEO of Elastin Bioscience

Francesca Lugarini

Francesca Lugarini

Entrepreneur in residence, CEO of SeneXell

Alexander Fedintsev

Alexander Fedintsev

Scientific director of Elastin Bioscience

News

Ivan Morgunov (founder of Longaevus Technologies), Sherif Idriss (CEO of Elastin Therapeutics (Longaevus’ spin-off)), Francesca Lugarini (CEO of SeneXell Project (Longaevus’ spin-off)) and Alexander Fedintsev (a specialist in extracellular matrix biology and advisor of Longaevus Biotech) at Bio-Europe 2023 in Munich, Germany.
The Longaevus team took part in BIO-Europe

The participation of the Longaevus Technologies team in the 9th annual BIO-Europe event held on November 6-8, 2023 in Munich, Germany.

Longaevus Technologies is proud to announce the release of Elastin Biosciences, a significant breakthrough in the field of elastin-related health.
Longaevus Technologies announced the allocation of Elastin Biosciences

Longaevus Technologies is proud to announce the release of Elastin Biosciences, a significant breakthrough in the field of elastin-related health.

Longaevus Technologies has received a grant from HEALS

HEALS has awarded a grant for a project to extend the life of mice and counteract numerous age-related cell changes.